Cargando…

Neo-Adjuvant Chemotherapy Reduces, and Surgery Increases Immunosuppression in First-Line Treatment for Ovarian Cancer

SIMPLE SUMMARY: The immune system plays an important role in the development and progression of cancer. The current treatments for ovarian cancer (surgery and chemotherapy) create changes in the immune system, but it is not clear how. Nevertheless, if immunotherapy is associated on top of this, then...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Bruyn, Christine, Ceusters, Jolien, Landolfo, Chiara, Baert, Thaïs, Thirion, Gitte, Claes, Sandra, Vankerckhoven, Ann, Wouters, Roxanne, Schols, Dominique, Timmerman, Dirk, Vergote, Ignace, Coosemans, An
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656504/ https://www.ncbi.nlm.nih.gov/pubmed/34885008 http://dx.doi.org/10.3390/cancers13235899

Ejemplares similares

Effect of Particle Carriers for Intraperitoneal Drug Delivery on the Course of Ovarian Cancer and Its Immune Microenvironment in a Mouse Model
por: Wouters, Roxanne, et al.
Publicado: (2022)

Type of chemotherapy has substantial effects on the immune system in ovarian cancer
por: Vankerckhoven, Ann, et al.
Publicado: (2021)

Opposite Macrophage Polarization in Different Subsets of Ovarian Cancer: Observation from a Pilot Study
por: Vankerckhoven, Ann, et al.
Publicado: (2020)

Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer
por: Baert, Thaïs, et al.
Publicado: (2019)

Preclinical studies performed in appropriate models could help identify optimal timing of combined chemotherapy and immunotherapy
por: Berckmans, Yani, et al.
Publicado: (2023)

Intraperitoneal alpha therapy with (224)Ra-labeled microparticles combined with chemotherapy in an ovarian cancer mouse model
por: Wouters, Roxanne, et al.
Publicado: (2022)

Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer
por: Sprooten, Jenny, et al.
Publicado: (2021)

Ovarian cancer and the immune system
por: Baert, Thaïs, et al.
Publicado: (2017)

Immunological parameters as a new lead in the diagnosis of ovarian cancer
por: Baert, T., et al.
Publicado: (2015)

The dark side of ID8-Luc2: pitfalls for luciferase tagged murine models for ovarian cancer
por: Baert, Thaïs, et al.
Publicado: (2015)

Experiences and well-being of healthcare professionals working in the field of ultrasound in obstetrics and gynaecology as the SARS-CoV-2 pandemic were evolving: a cross-sectional survey study
por: Bourne, Tom, et al.
Publicado: (2022)

CT-2A neurospheres-derived high-grade glioma in mice: a new model to address tumor stem cells and immunosuppression
por: Riva, Matteo, et al.
Publicado: (2019)

A view on dendritic cell immunotherapy in ovarian cancer: how far have we come?
por: Coosemans, A., et al.
Publicado: (2015)

Drug Repurposing for Targeting Myeloid-Derived Suppressor-Cell-Generated Immunosuppression in Ovarian Cancer: A Literature Review of Potential Candidates
por: Berckmans, Yani, et al.
Publicado: (2023)

Dendritic cell-based immunotherapy in ovarian cancer
por: Coosemans, An, et al.
Publicado: (2013)

Reactive Nodular Fibrous Pseudotumor: Case Report and Review of the Literature
por: Salihi, Rawand, et al.
Publicado: (2014)

Organoids of epithelial ovarian cancer as an emerging preclinical in vitro tool: a review
por: Dumont, Sander, et al.
Publicado: (2019)

Validation of models to diagnose ovarian cancer in patients managed surgically or conservatively: multicentre cohort study
por: Van Calster, Ben, et al.
Publicado: (2020)

Nutraceuticals in prostate cancer therapeutic strategies and their neo-adjuvant use in diverse populations
por: Reed, Dominique, et al.
Publicado: (2018)

Immunological configuration of ovarian carcinoma: features and impact on disease outcome
por: Fucikova, Jitka, et al.
Publicado: (2021)

Cancer surgery induces inflammation, immunosuppression and neo-angiogenesis, but is it influenced by analgesics?
por: Forget, Patrice, et al.
Publicado: (2013)

Nucleosome footprinting in plasma cell-free DNA for the pre-surgical diagnosis of ovarian cancer
por: Vanderstichele, Adriaan, et al.
Publicado: (2022)

CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer
por: Slagter, Astrid E., et al.
Publicado: (2018)

Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial
por: Di Cosimo, Serena, et al.
Publicado: (2020)

Predicting the response of localised oesophageal cancer to neo-adjuvant chemoradiation
por: Gillham, Charles M, et al.
Publicado: (2007)

Colorectal Cancer in the Elderly Patient: The Role of Neo-adjuvant Therapy
por: Dodaro, Concetta Anna, et al.
Publicado: (2019)

The role of neo-adjuvant therapy in cholangiocarcinoma: A systematic review
por: Cremen, Sinead, et al.
Publicado: (2022)

The emerging landscape of neo/adjuvant immunotherapy in renal cell carcinoma
por: Dibajnia, Pooya, et al.
Publicado: (2023)

Multiclass risk models for ovarian malignancy: an illustration of prediction uncertainty due to the choice of algorithm
por: Ledger, Ashleigh, et al.
Publicado: (2023)

Successful treatment of gallbladder mixed adenoneuroendocrine carcinoma with neo-adjuvant chemotherapy
por: Song, Wu, et al.
Publicado: (2012)

Neo–adjuvant hormonal treatment for the undescendent testis – a benefit for the patient?
por: Stein, Raimund
Publicado: (2013)

Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy
por: Findlay, John M., et al.
Publicado: (2016)

Neo-adjuvant chemoradiotherapy; an opportunity in sphincter preserving procedure for rectal cancer
por: Mozafar, Mohammad, et al.
Publicado: (2014)

Optimizing (neo)adjuvant treatment of HER2-positive breast cancer
por: Basho, Reva K., et al.
Publicado: (2018)

The Successful Use of Neo Adjuvant Brentuximab Vedotin in the Treatment of BIA-ALCL
por: Allchin, Rebecca L., et al.
Publicado: (2020)

A systematic review of neo-adjuvant radiotherapy in the treatment of breast cancer
por: Ahmed, Muneer, et al.
Publicado: (2021)

Neo-Adjuvant Use of Sorafenib for Hepatocellular Carcinoma Awaiting Liver Transplantation
por: Minoux, Kate, et al.
Publicado: (2022)

Tissue-resident memory T cells in the era of (Neo) adjuvant melanoma management
por: Plunkett, Kai R., et al.
Publicado: (2022)

Immunocompetent Mouse Models in the Search for Effective Immunotherapy in Glioblastoma
por: Wouters, Roxanne, et al.
Publicado: (2020)

Preoperative HE4 and ROMA values do not improve the CA125 diagnostic value for borderline tumors of the ovary (BOT) – a study of the TOC Consortium
por: Braicu, Elena Ioana, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_4gqdq17mc287453n41cmfmig9p